Population-based screening by Biohit GastroPanel[®] biomarkers practically eliminates the risk of gastric cancer during a long-term follow-up
Biohit Oyj Press release Biohit GastroPanel[®] is a unique Finnish innovation intended for a non-invasive diagnosis of the patients with dyspeptic (upper abdominal) complaints to confirm or exclude the presence of Helicobacter pylori (Hp) infection and atrophic gastritis (AG) (1,2). Similarly, GastroPanel[® ]is the only test on the market that accurately monitors the regulation of the acid output in the stomach. Because Hp and AG are the most important risk conditions for gastric cancer (GC), GastroPanel[®] blood test is also particularly applicable for population-based screening